120
Participants
Start Date
August 31, 2010
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
Genotropin Pen
Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
MARK VII pen
Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
Genotropin Pen
Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
MARK VII pen
Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
Privatpraxis, Oldenburg
Istanbul University Istanbul Medical Faculty Department of Pediatric Health and Diseases, Çapa
Vestische Kinder- und Jugendklinik Datteln, Datteln
Praxis fuer paediatrische Endokrinologie, Niederrad
Fakultni Nemocnice Brno, Brno - Mesto
Privatpraxis, Gauting
Universitaetsklinik fuer Kinder und Jugendliche, Erlangen
Fakultni nemocnice Olomouc, Olomouc
Vseobecna fakultni nemocnice v Praze, Prague
Fakultni nemocnice v Motole, Prague
Sophia Kinderziekenhuis, Rotterdam
Juliana Kinderziekenhuis / Endocrinologie, The Hague
Narodny endokrinologicky a diabetologicky ustav, Ľubochňa
Detska fakultna nemonica s poliklinikou, II. Detska klinika, Bratislava
Sahlgrenska Universitetssjukhuset, Centrum for Endokrinologi och Metabolism (CEM), Gothenburg
Drottning Silvias barn- och ungdomssjukhus, SU/Ostra, Gothenburg
Barn och Ungdomsmedicinkliniken, Linköping
Barnmedicinkliniken N, Umeå
Ankara University Medical Faculty Department of Internal Diseases, Sihhiye
Salford Royal NHS Foundation Trust, Hope Hospital, Salford
Royal Hospital for Sick Children, Glasgow
St Thomas Hospital, London
Norfolk and Norwich University Hospital, Norwich
Lead Sponsor
Pfizer
INDUSTRY